12:00 AM
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Multikine regulatory update

Cel-Sci said it received and issued a response to a warning letter from FDA's Division of Drug Advertising, Marketing, and Communications (DDMAC) identifying comments...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >